<DOC>
	<DOCNO>NCT02457793</DOCNO>
	<brief_summary>This two-stage dose-escalation study ass safety , tolerability effect oral dose cobimetinib GDC-0994 administer combination patient histologically confirm , locally advanced , metastatic solid tumor standard therapy either exist proven ineffective intolerable .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Effects Cobimetinib GDC-0994 Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically cytologically document , locally advanced metastatic solid tumor standard therapy either exist proven ineffective intolerable Evaluable disease disease measurable Life expectancy &gt; = 12 week Adequate hematologic end organ function For female patient childbearing potential male patient partner childbearing potential , use effective form contraception continue use study duration 3 month follow discontinuation treatment drug Fluorodeoxyglucose positron emission tomography ( FDGPET ) avid disease baseline scan For enrollment part 2 , patient must meet following : Measurable disease No four prior systemic therapy locally advance metastatic cancer History prior significant toxicity another MEK inhibitor ERK inhibitor require discontinuation treatment Evidence visible retinal pathology assess ophthalmologic examination consider risk factor retinal vein thrombosis History glaucoma Intraocular pressure &gt; 21 mmHg measure tonometry Predisposing factor retinal vein occlusion ( RVO ) History RVO , neurosensory retinal detachment , neovascular macular degeneration Allergy hypersensitivity component cobimetinib GDC0994 formulation Palliative radiotherapy within 2 week prior first dose studydrug treatment Cycle 1 Experimental therapy within 4 week prior first dose studydrug treatment Cycle 1 Major surgical procedure significant traumatic injury within 4 week prior first dose studydrug treatment Cycle 1 , anticipation need major surgery course study treatment Anticancer therapy within 28 day prior first dose studydrug treatment Cycle 1 Current severe , uncontrolled systemic disease History clinically significant cardiac dysfunction History symptomatic congestive heart failure serious cardiac arrhythmia require treatment History myocardial infarction within 6 month prior first dose studydrug treatment Cycle 1 History congenital long QT syndrome QTc &gt; 470 msec LVEF History malabsorption condition would interfere enteral absorption Clinically significant history liver disease , current alcohol abuse , current know active infection HIV , hepatitis B virus , hepatitis C virus Any condition require warfarin thrombolytic anticoagulant Active autoimmune disease Uncontrolled ascites require weekly large volume paracentesis 3 consecutive week prior enrollment Pregnancy , lactation , breastfeed Known brain metastasis untreated , symptomatic , require therapy control symptoms No history ongoing malignancy would potentially interfere interpretation Pharmacodynamic ( PD ) efficacy assay</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>